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Objectives: Establish the release kinetics of new chlorhexidine particles incorporated in a 
dental resin, and with the application of ultrasound.  
Methods: Spherical chlorhexidine particles (SCP) were synthesized (5 wt. %), freeze dried 
and incorporated into UDMA-HEMA resins. Chlorhexidine diacetate (CDP) (5 wt. %) was 
similarly incorporated in separate resins. Resin discs were immersed in deionized water, and a 
release profile established (650 h). Ultrasound was used to trigger chlorhexidine (CHX) release 
from the resin discs at specific durations (10-30s) and time intervals (1 to 425 h). Chlorhexidine 
content was determined by UV-Vis absorption. The chlorhexidine particles/polymer 
composites were characterized using TGA, SEM, and confocal microscopy.  
Results: SCP exhibited structures with high chlorhexidine content (90-95%), and a Mean (SD) 
diameter of 17.2 (2.5) µm which was significantly (p<0.001) smaller than the CDP crystals at 
53.6 (33.7) µm. The SCP discs had a lower (7.7%) CHX release compared to the CDP group 
(16.2%). Ultrasonication of the resin discs with increasing durations (10-30 s) resulted in higher 
drug release rates. CDP release rates (CHX) over 650 h were: 23.5% (10s), 42.6% (20s), 51.2% 
(30s), and for SCP (CHX) were; 9.8% (10s), 12.3% (20s), and 14.0% (30s). SEM/confocal 
microscopy revealed CDP discs exhibited dissolution associated with the particle surface and 
SCP from the interior. 
Significance: Chlorhexidine spheres incorporated in a dental resin demonstrated a responsive 
and lower CHX release. Ultrasound enhanced CHX release and is useful in clinical situations 
where the drug is required on demand to treat severe or persistent infections. 
 






Since being introduced to dentistry in the 1950s, dental composites have undergone 
considerable changes such as; the modification of fillers to enhance the mechanical properties 
and the optimisation of the polymeric matrix to improve their biocompatibility [1]. Currently 
available dental composites have exceptional aesthetics and comparable mechanical properties 
(flexural strength, fracture toughness and tensile strength) when compared with porcelain and 
amalgam, and superior to that of glass ionomers [2]. This allows their wide use for anterior and 
posterior tooth restorations, as well as pit and fissure sealants [3]. Dental composites are cured 
by light and chemically initiated free radical polymerization which results in 2-5.63 vol. % 
shrinkage of the material [4]. This can lead to the formation of gaps between the restoration 
and the tooth [5]. Bacterial microleakage through these gaps can cause marginal discoloration, 
sensitivity, inflammation, recurrent caries and apical periodontitis [6]. Furthermore, 
accumulation of bacterial biofilms on the surface of dental composites can lead to degradation 
of the polymer matrix, resulting in the weakening of the restoration. Dental composites with 
antimicrobial properties are therefore highly desirable to overcome these problems.  
Chlorhexidine is a bis-biguanide antiseptic and disinfectant that has a bactericidal and 
bacteriostatic action against a wide range of gram-positive and gram-negative bacteria [7, 8], 
and has been incorporated in a variety of resin composites [9-11]. Chlorhexidine also stabilizes 
the resin-dentine bond by inhibiting matrix metalloproteinases (MMP) which are responsible 
for the breakdown of the bond at the dentine-restoration interface [12]. Inclusion of 
chlorhexidine into dental composites has been achieved by mixing the chlorhexidine diacetate 
with monomers [13-15]. This composite however suffers from an uncontrollable release of 
chlorhexidine, due to its rapid diffusion from the methacrylate based resin. To overcome these 
drawbacks efforts have been made to develop new chlorhexidine formulations [16-19] and 
investigate novel drug carriers [20, 21], to control chlorhexidine release. Ultrasound is another 
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method previously used to control the release of antibacterial agents in bone cements, where 
the synergistic effect of ultrasound and antibiotics enhanced antimicrobial efficiency [15, 22]. 
More recent studies utilised high frequency ultrasound to deliver antimicrobial chitosan 
nanoparticles into dentinal tubules, which may open up new approaches for the treatment of 
root canal infections [23, 24]. 
Recently Luo et al. [25] developed a novel chlorhexidine compound, with unique spherical 
morphology and the ability to provide controlled release of chlorhexidine. The aim of this study 
was therefore to investigate the effects of ultrasound from a dental scalar (ultrasound probe); 
to enhance drug release from novel chlorhexidine spheres in a light cured dental resin. 
Ultrasound triggered chlorhexidine release may be particularly useful in developing triggered 






2. Materials and Methods 
 
2.1 Fabrication of spherical chlorhexidine particles 
Chlorhexidine spheres were fabricated and characterized as described previously [25]. Briefly, 
15mg/ml chlorhexidine diacetate (Sigma-Aldrich, Lot: 19H0417) solution and 0.33 M CaCl2 
(Sigma-Aldrich, Lot: SLBF7416 V) solution were mixed at 1:1 ratio by volume at room 
temperature. The mixture was shaken for 1 min, and then centrifuged at 2000 rpm for 1 min 
(Eppendorf centrifuge 5417C, Germany). The sedimentation was then washed three times with 
0.33 M CaCl2 solution and then centrifuged again. Thereafter, the product was freeze dried 
(ScanVac Cool Safe Freeze Drying, Denmark) at -107 ℃, 0.009 mBar for 1 day, and was used 
for all the following experiments. Several reproducible batches (3) were produced for this work. 
 
2.2 UV/VIS Spectroscopy and TGA Analysis 
The content of chlorhexidine in the spherical particles was determined by UV-Vis absorption 
(Lambda 35, Perkin Elmer, USA). Initially, a series of chlorhexidine diacetate aqueous 
solutions with standard concentrations of 0.25, 1, 2, 3, 4, 5, 10, 20 ppm were prepared, and the 
absorption measured. The absorption peak at 254 nm and the reference concentration had a 
linear relationship, and a standard curve of absorption verses concentration was established 
(Figure S1). Residual chlorhexidine in all the supernatants was determined by measuring the 
UV absorption of the supernatants at 254 nm, and then calculating the concentration using the 
calibration curve. The proportion of chlorhexidine in the spherical particles was then calculated 
by subtraction (initial CHX – CHX in all supernatants = CHX in the particles). In addition, the 
freeze dried chlorhexidine spheres; chlorhexidine diacetate and CaCl2 powder were analyzed 
using Thermo-gravimetric analysis (TGA Q50, USA). The TGA was carried out at 10°C/min 




2.3 Preparation of chlorhexidine UDMA- HEMA resin discs  
The resin was prepared by mixing 64% urethane dimethacrylate (UDMA) (Esschem, UK, Lot: 
591-22), 36% hydroxyethyl methacrylate (HEMA) (Aldrich, UK), 0.08% of N, N-dimethyl-P-
toluidine (Acros Organics, UK) and 0.05% dimethylamino ethyl methacrylate (Aldrich, UK). 
The mixture was stirred at 800 rpm for 15 min (VWR Stirrer, USA). Finally, camphorquinone 
(Aldrich, UK) was added at the proportion of 0.1% and the mixture was stirred for another 15 
mins. The current resin was selected as it was biocompatible when exposed to L929 fibroblasts 
(ISO 10993) and following a 28 day resin leach out study and DNA assay. Freeze dried 
spherical chlorhexidine particles were weighed (Salter Ander-180A weighing scale, UK) and 
incorporated within the resin at 5 wt% (chlorhexidine content), then placed in an Eppendorf 
tube and mixed for 15 s in a rotomix mixer (120V/60Hz, 2850 rotations/min) (ESPE RotoMix, 
USA). A separate set of samples containing chlorhexidine diacetate powder (5 wt% 
chlorhexidine content) was also incorporated in the prepared resin in the same way. The resin 
mixture was then placed into a Teflon mold (10 mm diameter × 2 mm depth) and cured through 
a Mylar film strip using a curing light (Bluedent LED pen, Bulgaria) (430-490 nm, 600 
mW/sq.cm) for 30 s on both sides. The discs were next weighed on a microbalance (Salter 




2.4 Labelled chlorhexidine particles and confocal microscopy 
For visualization of the chlorhexidine sphere distribution in the resin composites, the spheres 
were labelled using rhodamine B (Sigma, Lot: 063K3407). Spherical chlorhexidine particles 
were synthesized as described in section 2.1; however before mixing the chlorhexidine 
diacetate solution with the CaCl2 solution, 100 µl of rhodamine B (1 mg/ml) was added. The 
synthesized particles were then centrifuged, washed and freeze dried as in section 2.1. The 
labelled spherical chlorhexidine particles (5 wt% chlorhexidine content) were mixed with 
UDMA-HEMA resin and placed into a mold (10 mm length, 10 mm width and 1 mm depth) 
and cured using a curing light as in section 2.3. The rhodamine B (RhB) labelled chlorhexidine 
particle resin specimen before and after immersion in water (650 h) was then characterized 
using confocal microscopy (Leica TS confocal scanning system, Germany). 
  
2.5 Chlorhexidine release kinetics 
In the release study, all UDMA-HEMA resin discs containing spherical chlorhexidine particles 
(SCP) or chlorhexidine diacetate powder (CDP) were stored in cuvettes containing 2 ml 
deionized water at room temperature. To measure the effect of ultrasound on the release kinetics 
specimens were split into 4 groups (n=3 per group) for each composite (SCP and CDP).  The 
specimen groups comprised; Gp1:0s, Gp2:10s, Gp3:20s and Gp4:30s ultrasound exposure. 
Specimens were treated with a single application of ultrasound at multiple time points. The 
ultrasound was delivered by contacting the disc specimen surface with an ultrasound probe 
(27-30 kHz, Piezon Master 400, Electro Medical Systems, Switzerland) at the following time 
points; 1h, 3h, 5h, 15h, 25h, 40h, 65h, 95h, 140h and 205h. Ultrasound was applied to the all 
the samples identically, with the ultrasound probe in contact with the surface of resin discs and 
moved around the sample during application. Following the last ultrasonic treatment (205h), 
release measurements were continued until 650 h (275h, 350h, 425h, 500h, 575h and 650h). 
Solutions from each time intervals were collected for the UV-Vis absorption tests (Lambda 35, 
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Perkin Elmer, USA) and replaced with fresh deionized water. The amount of released 
chlorhexidine was determined according to the established relationship of absorption and 
chlorhexidine concentration, and cumulative release curves were plotted. The rhodamine B 
labelled chlorhexidine particle resin specimen was also immersed in water for 650h and fresh 
water added at each time interval.  
 
To further investigate the effect of ultrasound on triggering chlorhexidine release, another set 
of experiments with the same time intervals and release measurements was conducted on the 
two composite materials. The first group 1 received no ultrasound treatment. Ultrasound (30s) 
was next delivered to the disc specimens at the start of the experiment (0h, Gp.2); at the start 
and at 205h (14.3 h1/2) (Gp. 3) and at the start, 205h (14.3 h1/2) and 425h (20.6 h1/2) (Gp. 4). 
The release profile of each group with different treatment times for each material was compared. 
The slope of release curves after each of ultrasound treatment was determined by Δy/Δx and 
compared with that of the control. 
 
2.6 Scanning electron microscopy 
Chlorhexidine diacetate powder (C6143, Lot: 19H0417, CDP) and spherical chlorhexidine 
particle (SCP) powder  samples were prepared by  placing powder suspensions onto  the surface 
of glass slides,  which were stuck onto SEM stubs, and then dried in air. Resin discs containing 
CPD or SCP from each group before and after the ultrasonication study (sections 2.3, 2.5), were 
dipped into liquid nitrogen and broken. Cross-sections were mounted onto SEM stubs. All the 
samples were gold coated for 45s at 18 mA, 0.04 mBar using a sputter coater (SC7620, Emitech, 
UK). All samples were characterized using a scanning electron microscope (FEI Inspect-F, 
USA), in the secondary electron imaging mode. An accelerating voltage of 10 kv, spot size of 
3.5 and working distance of 10 mm was used. Multiple images (10) were collected for each of 
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the samples. The Mean (SD) particle diameter and size range of the chlorhexidine spheres and 
chlorhexidine diacetate particles was measured using quantitative image analysis (Sigma Scan 
Pro 5, Systat Software Inc., UK) of the SEM images. Over 100 particles were measured and 
the data was compared using a t test (Sigma Stat, version 2.03, SPSS Inc., Chicago, IL, USA), 




3.1 Results of the SEM study 
 
The results of the SEM study show a wide particle distribution (6.4-194.7 µm) of 
angular/tabular chlorhexidine diacetate crystals (Figures 1a, c), with a Mean (SD) diameter of 
53.6 (33.7) µm. The spherical chlorhexidine particles (Figures 1b, d) however, produced a 
narrower particle size range (6.3-21.7) and a Mean (SD) diameter of 17.2 (2.5) µm. The particle 
size data was compared using a t test and the chlorhexidine particle group showed a 
significantly lower (p<0.001) Mean particle diameter than the chlorhexidine diacetate group. 
SEM photomicrographs of cross-sectional images of the UDMA-HEMA resin discs containing 
spherical chlorhexidine particles and chlorhexidine diacetate powder are shown in Figures 1e 
and 1f. The morphology of the novel spherical chlorhexidine particles allowed the resin to 
finely penetrate the interior structure of the particles (Figure 1f). This was in contrast to the 
resin interaction with the angular and irregular morphology of the tabular chlorhexidine 
diacetate crystals, which exhibited resin penetration on its external surfaces (Figure 1e). Cross 
sectional images of resin composite discs after ultrasonic treatments (10-30 s) indicated an 
increasing gap between the chlorhexidine diacetate crystals and the resin, with a Mean (SD) 
gap of 6.68 (1.33) µm (10s, Figure 4c), 10.74 (0.87) µm (20 s) and 13.94 (1.87) µm (30 s). 
Dissolution of the particle interior was in evidence in the spherical chlorhexidine particle resin 




3.2 Results of the Thermo-gravimetric analysis 
The results of the TGA analysis are shown in Figure 2. After increasing the temperature to 800℃ 
the CaCl2 powder had 74 wt%, chlorhexidine diacetate had 4 wt% and the spherical 
chlorhexidine spheres had 8.5 wt% remaining. The decomposition temperature of the 
chlorhexidine spheres (210℃) was also higher than the chlorhexidine diacetate crystals 
(120℃). 
 
3.3 Release kinetics of chlorhexidine from resin discs 
The proportion of chlorhexidine in the spherical particles was determined to be 90-95 wt% 
according to the UV-Vis absorption results and calculating using the calibration curve (Figure 
S1). The release process of chlorhexidine from the spherical chlorhexidine particle filled resin 
showed a two stage release. The first stage is a slow release stage which lasted up to 205 h 
(14.3 h1/2), followed by a relatively rapid release which lasted till the end of the experiment at 
650 h (Fig. 3b). Chlorhexidine diacetate showed a more single stage release in comparison, 
which lasted till 205 hours after which the release indicates it was starting to plateau (Fig. 3a). 
Without any ultrasonic’s, chlorhexidine diacetate filled resin discs released 16.2% 
chlorhexidine (Fig. 3a), whereas the chlorhexidine sphere filled resin discs released 7.7% 
chlorhexidine at 650 h (Fig. 3b). The effect of ultrasound on chlorhexidine release kinetics was 
significant, with longer sonication durations giving higher release rates. The cumulative release 
for chlorhexidine diacetate incorporated resin discs (650 h) was; 23.5% (10s), 42.6% (20s), 
51.2% (30s), and for chlorhexidine sphere resin discs was; 9.8% (10s), 12.3% (20s), and 14.0% 
(30s) (Figures 3a, 3b).  
To further demonstrate the sensitivity to ultrasound and to control the release kinetics of 
chlorhexidine from the UDMA-HEMA resin discs, ultrasound was also carried out at specific 
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time intervals (0h, 14.3 h1/2 and 20.6 h1/2). The chlorhexidine release kinetics of resin discs for 
each ultrasound treatment is illustrated in Figures 3c and 3d. For the chlorhexidine diacetate 
resin discs (Figure 3c), the influence of 30 s ultrasonication (0 h) indicated a moderate 
chlorhexidine burst release, and for the second ultrasonication treatment (14.3 h1/2), a more 
dramatic burst release, and the third ultasonication (20.6 h1/2) produced a final responsive 
release indicated by the change in slope (Table 1). In comparison, the chlorhexidine sphere 
resin discs were less sensitive to the ultrasonication after 30 s ultrasonication (0 h, Figure 3d), 
and there was a delay until 150 h (12 h1/2), where there was a small increased drug release. The 
second (14.3 h1/2) and third (20.6 h1/2) ultrasonication, however led to a change in slope (Table 
1) and evidence of a responsive chlorhexidine release. 
 
3.4 Confocal microscopy results 
Confocal images of the labelled (RhB) chlorhexidine spheres inside the UDMA-HEMA resin 
can be seen in Figures 4a, b. The dendritic structure is revealed at the red channel fully intact 
before the release experiment (Fig. 4a). Figure 4b indicates the particle following the release 
experiment showing dark areas within the particle radiating from the central portion, but with 
the particle /resin interfaces still largely intact. These results indicated partial dissolution of the 
RhB associated with the particle center, and the presence of large amount of residual RhB still 







Due to its low solubility chlorhexidine is most commonly used in the form of chlorhexidine 
digluconate and chlorhexidine diacetate [7, 8]. The problems concerned with applying 
chlorhexidine digluconate or incorporating chlorhexidine diacetate crystals into gels, wound 
dressings or resins for antimicrobial applications is their rapid release and the difficulty of 
achieving  a sustained long term antibacterial effect [26]. A sustained drug release over a long 
time period is beneficial to effectively suppress bacterial growth and eliminate biofilms [27]. 
To achieve sustained release of chlorhexidine numerous carriers were studied, including 
microporous silica’s [28] and polymeric micro and nanoparticles [29, 30], but low drug loading 
capability and the difficulty of controlling the release were problems. Complexing of 
chlorhexidine/ chlorhexidine digluconate with cyclodextrin and encapsulation using an 
emulsion-solvent evaporation technique and compression into chips also resulted in low drug 
loading efficiency (9-16.8 %) [31]. 
The approach in the current study was based on the co-precipitation of chlorhexidine diacetate 
with a CaCl2 to produce spherical chlorhexidine particles, with a controlled size range (6.3-
21.7), dendritic morphology and large surface area (Fig 1b, 1d). This was in contrast to the 
chlorhexidine diacetate crystals with irregular and tabular morphology (Figs. 1a, 1c), with a 
significantly (p<0.001) larger crystallite size and broader size range (6.4-194.7 µm). The 
current synthesis process allowed the nucleation and growth of crystallites, where the Cl- 
anions were thought to be associated with the precipitation of the crystallite and the cation 
coordinated with the structure of the chlorhexidine [25]. A high chlorhexidine content (90-95 
wt%) as determined by UV-Vis absorption was also achieved. TGA confirmed the weight loss 
for the CaCl2· 2H2O was 26 wt. %, which was thought to be due to the loss of H2O (theoretically 
is 24.5 wt%). It was therefore assumed that the CaCl2 did not decompose (Figure 2). The 
remaining 4 wt% for chlorhexidine diacetate may be associated with degradation products, 
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whilst the increased 4.5 wt% (remaining weight of spherical CHX particles – remaining weight 
of chlorhexidine diacetate/degradation products) was ascribed to the CaCl2 in the spherical 
particles. Chlorhexidine compounds have been synthesized by mixing chlorhexidine 
digluconate and sodium hexametaphosphate solutions together to produce antibacterial 
chlorhexidine hexametaphosphate nano-particles and aggregates for use in glass ionomers and 
biomedical applications [17, 18]. Other chlorhexidine formulations based on the coordinating 
ability of biguandines with metal ions (Cu2+, Zn2+, Sn2+, Ag+), were also reported, but with no 
structure or morphology of the complexes revealed [19, 32, 33]. The current formulations 
produced a specific and reproducible crystallite size and morphology which did not suffer from 
aggregation behavior or any potential issues with nano-toxicity [34], which might affect nano-
materials without a carrier.  
 
The release kinetics of the chlorhexidine diacetate and chlorhexidine spheres incorporated in 
the UDMA-HEMA resins were evaluated before the application of ultrasonics. With an 
equivalent amount of chlorhexidine (5 wt%), the resin discs containing the chlorhexidine 
spheres had a lower chlorhexidine release (7.7%), compared to that of chlorhexidine diacetate 
(16.2%) after 650 h water storage (Figures 3a, 3b). It was also apparent from the change in 
slope (Table 1) that the chlorhexidine diacetate release data appeared to show signs of a plateau 
compared with the chlorhexidine sphere specimen data over 650 h. It was assumed that higher 
solubility of chlorhexidine diacetate compared with the spherical chlorhexidine compounds 
was in part due to the presence of Ca2+ and Cl- in the structure and associated with the different 
release kinetics observed. Zeng et al. [7] commented that the quantity of chlorhexidine in 
solution was associated with the types of ion in solution, with lower concentrations when 
dichlorides were present due to structural solubility. It was thought that when the 
dihydrochloride salts KSP was lower than the diacetate salt, the formation of a low solubility 
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chlorhexidine dihydrochloride was more thermodynamically possible [35]. The higher release 
data for chlorhexidine diacetate incorporated into resins has also been linked to higher levels 
of residual monomer, caused by inhibition of the polymerization process [36]. A correlation 
between rapid chlorhexidine release rates and water sorption of the polymer was reported, due 
to the presence of unreacted monomer and hydrophilic resin components [37]. The stabilization 
of free radicals by chlorhexidine diacetate addition may also slow the termination step in 
polymerization of HEMA, TEGDMA and UDMA resin blends [38]. The release mechanism 
was thought to be due to droplet formation around the chlorhexidine salt, and with drug 
diffusion dependent on such droplets linked to the surface via the formation of pathways or 
channels [39]. Another factor may be the increased surface area of spherical chlorhexidine 
particles allowing the polymer resin (UDMA-HEMA) to finely penetrate their interior structure 
(Figure 1f). SEM and confocal microscopy confirmed the efficacy of the resin penetration and 
RhB labelling suggests some preservation of the chlorhexidine within the polymer before water 
storage (Figure 4a). Rhodamine B dissolution from the particle interior following the release 
experiment (650 h water storage, no ultrasonics) might indicate that partial drug dissolution 
within the chlorhexidine sphere (Figure 4b) may have occurred. The interaction of the resin 
with the larger and angular morphology of the tabular chlorhexidine diacetate crystals was on 
its external surfaces (Figure 1e) which may have encouraged increased water sorption. Inagaki 
et al. [40] commented on the importance of the chemical composition of the monomer in resin 
blends containing chlorhexidine, their water sorption, polymerization and plasticization, with 
chlorhexidine dissolved with unreacted monomer causing spaces between the polymer bulk. 
 
The release profile of chlorhexidine diacetate from the resin composite was a complicated 
process, with dissolution of the drug by a burst release from the surface initially, followed by 
a sustained diffusion controlled release (Figure 3a) and similar to other studies [37, 39]. 
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Mechanisms for burst released were reviewed by Haung and Brazel [41],  and one reason was 
drug entrapment on or near the surface and instantaneous leaching in water, and a lack of 
physiological or chemical binding to the polymer network [22]. Subsequent diffusion of water 
into the resin matrix and drug dissolution leads to porosity, allowing further drug diffusion at 
interconnected pores, and affecting release rates at higher drug loading [42]. According to the 
release profile in Figure 3a (0s group), most of the incorporated chlorhexidine diacetate 
remains trapped within the resin composite, with the release increased from 16.2-51.2% at 650 
h using ultrasonics (0-30 s treatments). Triggers such as ultrasound are useful to release any 
remaining drug especially when the concentration of released antimicrobial agents is below the 
minimum inhibition concentration (MIC). This method has previously been  reported to 
increase gentamicin and vancomycin release from acrylic bone cements [22], which resulted 
in enhanced in vivo bacterial inhibition and inflammation relief [15]. Chlorhexidine release was 
enhanced by ultrasound treatment for both the chlorhexidine diacetate and chlorhexidine sphere 
resin composites, with longer ultrasonication time (10 to 30s) enhancing chlorhexidine release 
(Figs. 3a, 3b). It is feasible that micro streaming induced by ultrasound was the main reason, 
and with cavitation in the low-frequency range (18-100 kHz) [43], which is beneficial for fluid 
exchange and encouraged chlorhexidine to diffuse out [44]. An aqueous channel/pathway is 
required for chlorhexidine release from resin composites, so the influence of ultrasonication on 
this process may be dramatic. In particular, removal of residual monomer has been 
demonstrated in auto-polymerized PMMA at low ultrasonic frequency (28 kHz) [45]. The 
thermal effects generated by ultrasonication should also be taken into consideration [46], since 
the influence of ultrasound on gentamicin release was equal to a 3°C increase in temperature 
[22]. Clinical applications in dentistry often report higher ultrasonication temperatures (>10°C), 
but this is dependent on the equipment set up and application [47]. It can be assumed that heat 
generated during ultrasonication may have assisted the dissolution of chlorhexidine compounds 
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in the resin composites. Increased water sorption, solubility and cracking in HEMA containing 
polymer blends is also reported at higher temperatures [48]. 
 
Ultrasonication of the resin samples containing chlorhexidine spheres exhibited lower level 
drug release (9.8-14%), via a step wise process and showed no signs of a plateau at 650 h. This 
behavior was also illustrated when ultrasonication was used at different time points (start, 14.3 
h1/2, 20.6 h1/2), but with a clear change in slope at the 14.3 h1/2, 20.6 h1/2 showing a responsive 
drug release (Figure 3d, Table 1). Ultrasonics (30 s) at the start (0h) showed little change in 
slope (0-3 h) compared no ultrasonics (Table 1), but with a later release onset (150 h, 12 t ½). 
This may be related to the morphology, chemical composition and resin penetration of the drug 
spheres and the time taken to penetrate the polymer with water, as a more responsive release 
was noted for later ultrasonic treatments (Figures. 1b, 1d). This reservoir or storage effect until 
the structure is penetrated by water [41], influencing the release kinetics and retention rate of 
chlorhexidine. The chlorhexidine diacetate resin specimens subjected to 30 s ultrasonics at the 
start (0h)  produced a higher drug release, with a more responsive burst release similarly evident 
once the polymer had been exposed to longer water storage by the 14.3 h1/2 treatment (Figure 
3c). Water uptake studies of the unfilled resin in the current study indicated that equilibrium 
was reached within this time period but is dependent on the resin composition, hydrophilicity 
and crosslink density [49]. 
 The particle size, surface area, morphology and chemistry of incorporated chlorhexidine 
compounds may have an influence on the release kinetics of the respective particles added.  
The larger size (Mean diameter (SD)) of 53.6 (33.7) and tabular morphology of the 
chlorhexidine diacetate crystals were more sensitive to the effects of ultrasound than the 
homogeneous and smaller spheres (Figures 1d, 1f). The morphology of the solid chlorhexidine 
diacetate particle and cleavage planes (Figures. 1c and 1c) may be more susceptible to solubility, 
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and damage by collapse cavitation, high velocity ultrasonic shock waves and other processes 
[50], since more dramatic burst release was observed corresponding to each of the ultrasound 
treatment at 14.3 h1/2, 20.6 h1/2 (Fig. 3c). Cross-sectional images of resin composite discs after 
ultrasonic treatments (10-30 s) indicated an increasing Mean (SD) gap width between the 
chlorhexidine diacetate crystals and the resin of 6.68 (1.33)µm  (10s, Figure 4c) to 13.94 (1.33) 
µm (30 s). It was therefore thought that this was largely a surface dissolution process, whereas 
the chlorhexidine sphere dissolution was associated with the sphere center (Figures 4b, 4d). 
Certainly the close adherence of hydrophobic polymer clusters [51] within the interior structure 
of the drug sphere may have influenced this process. Increased drug release with longer 
ultrasonication time (10-30 s) was associated with cracks and central sphere damage (Figure 
4d). Oscillation, high fluid shear forces and heat generated by cavitation during ultrasonication 
[46, 52] are potential causes [50], and accelerating the dissociation of chlorhexidine from the 
compounds. Further work is needed to asses any potential mechanical property changes to the 
resin composites suggested in the literature [42, 53], or via ultrasonic treatment. It is also 
possible to reduce spheres size using temperature control [25] or nucleation catalysts and tune 
the ultrasonic treatments to optimise these outcomes. 
Incorporation of novel chlorhexidine spheres with high drug content (90-95%) in UDMA-
HEMA resins and the use of ultrasound demonstrated a responsive and lower chlorhexidine 
release, compared to chlorhexidine diacetate over 650h water storage. Inclusion of the 
chlorhexidine spheres in a range of dental prostheses, via temporary soft lining materials and 
to treat denture stomatitis and a responsive ultrasonic drug release in maxillo-facial prostheses 
are realistic applications. The current results illustrate that these spherical chlorhexidine 
spheres may be beneficial in developing antibacterial dental composites and drug delivery 
systems to treat Periodontitis and Peri-implantitis. The authors have established the lack of 
cytotoxicity to fibroblasts and antimicrobial effectiveness of the chlorhexidine spheres, against 
18 
 
a range of bacteria associated with these diseases and at a safer concentration than in current 
products [54]. The application of restorative materials to the supra-bony parts of the exposed 
implant surfaces in patients with Peri-implantitis led to no further bone loss, stability and non-
inflamed soft tissues in the short term [55]. The current technology might be useful in these 
low stress bearing applications, with drug release enhanced through ultrasound application. 
This could provide potential benefits in clinical situations where more drug is required on 
demand, to safely treat relatively severe or persistent infections and with less risk of 
cytotoxicity. This could be extremely desirable in Medicine and Dentistry in the safe treatment 
of recurrent infections or carries.  
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Table 1,  Change in slope (SD) as a function of ultrasonication treatment. 
 
Table 1  
 
 
Measured slope range (SD)              0h-3h                     205h-275h               425h-500h 
Resin with CDP *                       1.93 (0.48)                   0.45 (0.028)                0.13 (0.03) 
Resin with CDP/ultrasonics        2.18 (0.63)                  4.40 (0.42)                  1.31 (0.55) 
Resin with SCP*                         0.21 (0.06)                  0.11 (0.02)                    0.09 (0.06) 
Resin with SCP/ultrasonics         0.22 (0.01)                  1.09 (0.54)                   0.87 (0.11) 
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Figure 1, SEM images showing the particle distribution of: (a) chlorhexidine diacetate 
crystals (CDP); (b) spherical chlorhexidine particles (SCP), and (c, d) 
individual particle morphology at high magnification (c=SCP, d=CDP); Cross-
sectional images of the UDMA-HEMA resin discs containing (e) chlorhexidine 
diacetate crystal  and (f) spherical chlorhexidine particles. 
 
Figure 2,  TGA of the spherical chlorhexidine particles, chlorhexidine diacetate and 
calcium chloride. 
 
Figure 3,  Release kinetics of the UDMA-HEMA resin discs containing; (a) chlorhexidine 
diacetate and (b) chlorhexidine spheres after repetitive ultrasound treatment at; 
0 s (black), 10 s (red), 20 s (blue) and 30 s (green) and terminated at the 14.3 
h1/2. Resin discs containing; (c) chlorhexidine diacetate and (d) chlorhexidine 
spheres after repetitive ultrasound treatment for 30s at the start (red), 30s at start 
and 14.3 h1/2 (blue) and 30s start, 14.3 h1/2 and 20.6 h1/2 (green). 
 
Figure 4,  Confocal images of UDMA- HEMA resin specimen containing rhodamine B 
  labelled spherical chlorhexidine particles; (a) before and (b) after 650 h water 
  storage; (c) SEM photomicrograph (and inset) of chlorhexidine diacetate resin   
  disc cross-section after 650 h water storage and repetitive ultrasound treatment 
  for 10 s; (d) SEM photomicrograph (and inset) of chlorhexidine particle resin   
  disc cross-section after 650 h water storage and repetitive ultrasound treatment 
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Arrows indicate ultrasonication time (h 1/2) 
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